Teva settles US antitrust case for $1.2b

Teva Pharmaceutical will pay $1.2 billion to settle US antitrust charges in a long-running “pay for delay” case involving Cephalon, which Teva acquired in 2012, the Federal Trade Commission says.

Israel-based Teva, the world’s largest generic drug manufacturer, agrees to make the money available to compensate buyers, including drug wholesalers, pharmacies and insurers, who overpaid for Cephalon’s blockbuster sleep-disorder drug Provigil because of that company’s illegal conduct.

Under the settlement, Teva also agrees to a prohibition in all of its US operations on the type of anticompetitive patent settlements that Cephalon used to artificially inflate the price of Provigil, according to the FTC.

The Jerusalem office of the Israeli drug company Teva Pharmaceuticals (photo credit: Yonatan Sindel/Flash90)
The Jerusalem office of the Israeli drug company Teva Pharmaceuticals (photo credit: Yonatan Sindel/Flash90)

The settlement stems from a 2008 FTC lawsuit against Cephalon alleging that the company unlawfully protected its monopoly on prescription drug Provigil from competition through so called “reverse-payment” deals with four generic drugmakers in 2005-2006.

AFP

Most Popular
If you’d like to comment, join
The Times of Israel Community.
Join The Times of Israel Community
Commenting is available for paying members of The Times of Israel Community only. Please join our Community to comment and enjoy other Community benefits.
Please use the following structure: example@domain.com
Confirm Mail
Thank you! Now check your email
You are now a member of The Times of Israel Community! We sent you an email with a login link to . Once you're set up, you can start enjoying Community benefits and commenting.